Nestlé Uses AI to Target GLP-1 Users

8 sourcesUpdated Aug 17, 2026

Nestlé is aiming to capitalize on the GLP-1 weight‑loss drug wave by using AI and nutritional science to create products for users of Ozempic and Wegovy, including formulations to mitigate side effects such as muscle and facial fat loss. The company views the rising GLP‑1 market as a major opportunity, with tens of millions of potential consumers and AI helping to accelerate research and tailor offerings. Separately, Eli Lilly and Novo Nordisk remain locked in a high-stakes market dynamic, with Lilly posting stronger quarterly revenue and a looming competitive spotlight as Novo Nordisk cuts its full‑year outlook and faces a patent-style advertising dispute over drug data. AstraZeneca signals that the GLP-1 arena extends beyond weight management, as executives stress differentiating strategies in this expanding field. Amid this growth, regulators warn about counterfeit and falsified GLP-1 medicines entering supply chains, underscoring safety and quality concerns as demand climbs. Overall, the GLP-1 landscape is merging rapid pharmaceutical innovation with consumer‑facing nutrition strategies and vigilant regulatory oversight.

In this story:

More on this story

Back to News

Photo: Etatics Inc. / Wikimedia Commons (Pexels)

UK Approves Foundayo Oral GLP-1 Pill; NHS Decision Pending

The UK has become the first European nation to approve Eli Lilly’s Orforglipron, sold as Foundayo, a once-daily GLP-1 pill for weight management and type 2 diabetes with specific BMI criteria and a multi-dose ramp-up. The MHRA emphasized prescription-only status and ongoing safety reviews, with NHS access still under consideration by NICE and not yet widely available.

64 sources

Khaligraph Jones 47 kg Weight Loss Reported

The Kenyan rapper Khaligraph Jones has shed 47 kg (from 137 kg to 90 kg) through an extreme regimen of multi-day fasting, ketogenic diet, and late-night workouts, prompting discussion among experts about safety and sustainability. He has publicly detailed routines including 80-hour fasts, four-day weekly fasting, and meals like salad and watermelon, sparking both admiration and caution about its health implications.

Right

133%

Other

5

Total sources8

Last updatedAug 17, 2026

Does this breakdown look right?

How it spread

Broke FoodDive · Aug 14, 3:37 AMCenter within the hourRight +10h8 sources +3d on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

How each side headlines it

Left· 0 sources

No left coverage yet — a bubble gap.

Center· 2 sources

“Nestle looks to develop products for users of GLP-1s”

RTE (Radio Television of Ireland) · Aug 17, 2026

Right· 1 source

“AstraZeneca Says the GLP-1 Market Goes Beyond Just Weight Loss”

Barron's · Aug 14, 2026

Coverage

RTE (Radio Television of Ireland)CenterNestle looks to develop products for users of GLP-1s

Barron'sLean RightAstraZeneca Says the GLP-1 Market Goes Beyond Just Weight Loss

globalbankingandfinance.comOtherNestle Develops New Products for GLP-1 Weight-Loss Drug Users

Comments

Ask this story anything:

Free account · your comment posts right after signup

6 sources

GLP-1 obesity drugs linked to fewer alcohol hospitalizations

A multi-trial analysis of about 40,700 adults found GLP-1 receptor agonists such as semaglutide and tirzepatide are associated with substantially lower alcohol-related hospital admissions across diabetics, obesity, and alcohol-use disorder groups, with reductions ranging from roughly 26% to 65% depending on the comparison. Experts say the findings hint at a potential role for these weight‑loss and diabetes drugs in treating alcohol-use disorders, though more research is needed to confirm causality and guide use.

9 sources